ChronosDx is building a new bioassay platform technology for drug assays on in vitro cell models and non-invasive diagnostics on body fluids. Our platform enables highly sensitive, precision quantification of a wide range of biomarkers: proteins, metabolites, microRNAs, cell-free DNA and exosomes. We’re combining low-cost fabrication and scalable production with our unique insights, developed over 4 years of research, on single-molecule detection and dynamic concentration ranges in a multi-omic platform, with capability for in-line and in vivo continuous monitoring of biomarkers. Our first target market is in vitro cell-based assays for cancer drug development and liquid biopsy for early cancer detection, with the technology having unique advantages for these high value areas.